End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
28.55 CNY | -0.80% | -0.49% | -7.72% |
04-12 | Tiantan Biological Products' Q1 Profit Jumps 21%; Shares Rise 7% | MT |
04-11 | Beijing Tiantan Biological Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 34.61 times its estimated earnings per share for the ongoing year.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.72% | 6.49B | C | ||
-4.06% | 86.13B | A- | ||
+1.32% | 39.82B | A- | ||
+56.59% | 25.23B | A | ||
-14.86% | 15.36B | C | ||
-9.14% | 11.95B | D+ | ||
-16.29% | 11.6B | B- | ||
-43.00% | 11.51B | B | ||
+5.92% | 8.71B | B+ | ||
-7.02% | 8.12B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600161 Stock
- Ratings Beijing Tiantan Biological Products Co., Ltd.